Motion Sickness — Class III drug recall D-0323-2020
Terminated recall by Sato Pharmaceutical Inc., reported 2019-11-20, distributed nationwide. Subpotent Drug
| Recall number | D-0323-2020 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Sato Pharmaceutical Inc., Torrance, CA, United States |
| Recall initiated | 2019-10-01 |
| Classified | 2019-11-13 |
| Reported by FDA | 2019-11-20 |
| Terminated | 2020-08-18 |
| Distributed | Nationwide (US) |
| Quantity | 210,744 units |
| Reason classes | potency |
| UPC / GTIN / UDI-DI | 00050428345535 |
| NDC | 59779-0534, 59779-0534-01 |
| Expiration dates | 2020-07-20, 2021-03-20, 2021-07-20, 2021-10-20, 2021-12-20 |
Product
Motion Sickness (meclizine hydrochloride) 25 mg tablets, 12-count box, Distributed by Sato Pharmaceutical INC. 20695 S. Western Ave., Suite 240 Torrence, CA 90501, NDC 59779-534-01. UPC 050428345535
Reason for recall
Subpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0323-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.